Background: High selenium status has been linked to elevated blood cholesterol levels in cross-sectional studies.
S
ince 1982, when Salonen and colleagues (1) showed a significant 2-to 3-fold increase in cardiovascular morbidity and mortality for persons with low serum selenium concentrations, there has been interest in the link between selenium status and cardiovascular disease. In theory, potential cardiovascular benefits are supported by the ability of selenoproteins, such as glutathione peroxidase and selenoprotein S, to combat the oxidative modification of lipids, inhibit platelet aggregation, and reduce inflammation (2) (3) (4) (5) (6) (7) (8) (9) . Despite a solid biological rationale for a beneficial effect of optimal selenoprotein activity and concentration on cardiovascular health, evidence that selenium status affects coronary heart disease risk is equivocal (10 -14) . In contrast to the putative benefits of selenium, several crosssectional studies have shown an association between higher selenium status and elevated plasma or serum concentrations of total or low-density lipoprotein cholesterol (15) (16) (17) (18) (19) (20) (21) (22) (23) . However, some studies have also linked higher selenium status to higher high-density lipoprotein (HDL) cholesterol levels (19, 20, 23, 24) . Although no effect of selenium supplementation on serum cholesterol level was found in 2 small trials (25, 26) because of their low power, we cannot conclude that the cross-sectional association observed between selenium and serum lipid levels is not driven by selenium.
The UK PRECISE (United Kingdom PREvention of Cancer by Intervention with SElenium) Pilot Study, in which 501 elderly volunteers were randomly assigned to receive 6-month treatment with 100, 200, or 300 mcg of selenium per day as high-selenium yeast or a placebo yeast (27, 28), provided a unique opportunity to investigate the effect of selenium supplementation on plasma lipids in a considerably larger group than has been studied previously. Based on previous observational evidence, our working hypothesis was that selenium supplementation would increase total plasma cholesterol levels, thus providing supporting evidence for the cross-sectional association. A secondary aim was to determine the relative contributions of HDL and non-HDL cholesterol levels to this effect.
METHODS

Design
The UK PRECISE Pilot Study for the planned international PRECISE trial was designed to assess the viability of conducting the trial in the United Kingdom. It was a double-blind, placebo-controlled, 4-group (allocation ratio was 1:1:1:1), parallel-group study stratified by age and sex and conducted at 4 sites in the United Kingdom (International Standard Randomised Controlled Trial Number Register registration number: ISRCTN25193534), as described elsewhere (27, 28). Funding was never secured for the international PRECISE trial, which did not therefore take place.
Sample
No formal power calculations were done for the pilot study, and the sample size (n ϭ 501) was chosen to give a sufficient number to be able to draw reasonable inferences about recruitment, adherence, and loss to follow-up while keeping the cost within reasonable bounds.
Setting and Participants
Volunteers were recruited from 4 general practices in different parts of the United Kingdom ( Table 1 ) affiliated with the Medical Research Council General Practice Research Framework. The local research ethics committees (South Tees, Worcestershire Health Authority, Norwich District, and Great Yarmouth and Waveney [under reciprocal arrangements with the Norwich District local research ethics committee]) approved the study, and participants provided written informed consent.
Randomization and Interventions
From June 2000 to July 2001, research nurses recruited similar numbers of men and women from each of 3 age groups: 60 to 64 years, 65 to 69 years, and 70 to 74 years. Exclusion criteria were a Southwest Oncology Group performance status score greater than 1 (that is, incapable of carrying out light housework or office work); active liver or kidney disease; a previous diagnosis of cancer (excluding nonmelanoma skin cancer); diagnosed HIV infection; receipt of immunosuppressive therapy at recruitment; diminished mental capacity; or receipt of selenium supplements, 50 mcg/d, in the previous 6 months (by patient report). Written informed consent was obtained from all participants after they had been given a detailed description of the study, time to consider, and the opportunity to ask questions.
Computer-generated, random, permuted blocks stratified by general practice, sex, and age group were used to generate a randomized list at the independent randomization service at the Clinical Trials and Statistics Unit, Institute of Cancer Research (Sutton, United Kingdom). The Medical Research Council General Practice Research Framework stockroom supplied the trial tablets to the practices according to this list. The research nurses in the practices telephoned the randomization service at the Clinical Trials and Statistics Unit, which had a dedicated telephone line, to obtain an anonymous code (that is, trial number) for each eligible volunteer. The volunteer was then given the precoded tablets bearing that trial number.
After a 4-week, placebo run-in phase, 501 volunteers were randomly assigned in equal numbers to receive 1 of 4 treatment regimens: placebo or 100, 200, or 300 mcg of selenium per day for a minimum of 6 months. The intervention agent was the high-selenium yeast SelenoPrecise (Pharma Nord, Vejle, Denmark) or an identical placebo yeast (comprising 250 mg of yeast placebo, 80 mg of cellulose, 65 mg of dicalcium phosphate, and Յ5 mg of other inactive ingredients). Demographic data; medical history; and other health-related information, including medication and supplement use, were collected at baseline. Participants provided a nonfasting blood sample at both baseline and 6 months.
Blinding and Outcomes
Participants, research nurses, other general practice personnel, investigators, and persons who analyzed the data
Context
Observational studies of selenium status offer conflicting evidence that deficiency is associated with heart disease, whereas nondeficiency is associated with dyslipidemia.
Contribution
In this randomized trial, selenium supplementation was associated with modest reductions in total and non-highdensity lipoprotein cholesterol levels. At higher doses, selenium supplementation was associated with increases in high-density lipoprotein cholesterol levels.
Caution
The trial lasted only 6 months and enrolled only older patients.
Implication
Selenium supplementation modestly improves lipid profiles. The findings more definitively identify the effects of selenium on lipids because they are trial-based. However, the findings do not justify the use of selenium for dyslipidemia because the clinical significance of the changes is unknown and selenium supplementation may have other side effects.
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Effect of Selenium Supplementation on Plasma Lipids were blinded to treatment. The defined prespecified primary outcome was satisfactory recruitment, retention, and adherence of the volunteers so that the viability of conducting the main PRECISE trial in the United Kingdom could be ascertained. Prespecified secondary outcome measures were the effect of selenium supplementation on mood and thyroid function (27, 28).
Nonspecified outcomes that were later examined on stored samples were based on literature reports that plasma total homocysteine concentration was inversely associated with plasma selenium concentration (29) and that plasma total cholesterol level was positively associated with plasma or serum selenium concentration. Thus, the effect of selenium supplementation on plasma total homocysteine and B vitamin concentrations were investigated, although only in the groups that received placebo and 100 and 300 mcg of selenium per day (for reasons of financial constraint) (29), and the effects of selenium supplementation on plasma total cholesterol and HDL cholesterol levels were measured in the current study.
Follow-up
The last planned 6-month follow-up visit (with blood draw) was in January 2002. However, volunteers, who were to be the first cohort of the main PRECISE trial, continued treatment and 6-month follow-up visits until mid-2003 when it became clear that the international study was not going to be funded.
Heparinized plasma was prepared and frozen at the practices. Plasma samples were transferred to the University of Surrey Guildford, United Kingdom, on dry ice, where they were stored at Ϫ80°C. At the 6-month follow-up visit, questionnaires were used to see whether any new symptoms or illnesses occurred since randomization and use of medication and supplements had changed. Adherence was assessed by pill count-participants were considered adherent if they took at least 80% of their allocated tablets. In addition, each participant's plasma selenium concentration was compared with the mean concentration of the group to detect any outliersnonadherent participants or "drop-ins" (nonprotocol use of over-the-counter selenium). Reasons for participant withdrawal were noted.
Selenium Measurement
Lithium-heparin plasma was analyzed for selenium at Central Science Laboratory, Sand Hutton, United Kingdom, by using hydride-generation inductively coupledplasma mass spectrometry, as described elsewhere (28). Accuracy was assured by good performance on the analysis of certified reference materials (28).
Plasma Lipid Measurement
Total and HDL cholesterol levels were measured on the remaining stored plasma samples (454 participants at The mean values for the quality-control total and HDL cholesterol samples were within the manufacturer's certified ranges. The intra-and interassay coefficients of variation were less than 1.4% for total cholesterol levels and less than 2.6% for HDL cholesterol levels.
Statistical Analysis
The effect of selenium supplementation on plasma levels of total, HDL, and non-HDL cholesterol and on the total-HDL cholesterol ratio was estimated by using linear mixed models for longitudinal data with random betweenparticipant variations in baseline lipid levels (intercepts) and lipid changes over time (slopes). The models are specified in detail in the Appendix (available at www.annals .org). Participants were randomly assigned to a group regardless of adherence (intention-to-treat assignment). The reported P values are 2-sided and were not adjusted for multiple testing. Analyses of covariance restricted to participants with lipid measurements available both at baseline and at 6 months (n ϭ 374) resulted in virtually identical results (data not shown).
In addition to the intention-to-treat analysis, we conducted additional analyses of the cross-sectional association between baseline plasma selenium concentrations and plasma lipids and analyses of the longitudinal association between change in plasma selenium concentrations and change in lipid levels. The cross-sectional analyses do not reflect the trial intervention but enable the results to be compared with those of previous observational studies ( [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The longitudinal analyses reflect the trial intervention and are equivalent to per-protocol analyses by using the observed change in plasma selenium concentrations as the exposure metric. Cross-sectional and longitudinal associations were obtained from random-intercept and randomslope linear mixed models for longitudinal data. The models are specified in detail in the Appendix. Statistical analyses were done with Stata, version 11 (StataCorp, College Station, Texas).
Role of the Funding Source
The Cancer Research Campaign (now Cancer Research UK) funded the UK PRECISE Pilot Study. The Cardiovascular Disease, Diabetes & Metabolism Research Theme, University of Surrey, provided funding for the lipid measurements. The funding sources had no role in the study design; data collection, analysis, or interpretation; or decision to submit the manuscript for publication.
RESULTS
Participants
Of 501 randomly assigned participants, 34 withdrew from treatment ( Figure) . There was no statistically significant difference in numbers of participants who withdrew across treatment groups (P ϭ 0.31). Our report is restricted to the 474 participants (94.6%) who had at least 1 lipid measurement available either at baseline or at 6 months (lipid measurements were available for 454 participants at baseline, 394 at 6 months, and 374 both at baseline and at 6 months) ( Figure) . Characteristics of participants with and without available lipid measurements did not differ (data not shown). A total of 94% of the 474 participants missed less than 10% of the total number of study tablets, according to pill count. Nonprotocol use of over-the-counter selenium (drop-ins) was assessed by inspection of the histogram of plasma selenium concentration in the placebo group at 6 months. Four of 107 participants who received placebo (3.7%) had a selenium status more than 2 SDs above the mean, which is reasonably consistent with the 2.5% expected by chance (being approximately normally distributed). We have assumed, therefore, that drop-ins were rare. Three participants reported receiving supplements containing 25 mcg of selenium. Because this was within the daily limit of 50 mcg imposed by our exclusion criteria, the participants have been included in the analysis. Twenty-two participants were receiving lipid-lowering medications, with no statistically significant difference across the groups ( Table 1) .
Intention-to-Treat Analysis
Overall mean plasma selenium concentration at baseline was 88.8 ng/g (SD, 19.2) (equivalent to 91.2 mcg/L [SD, 19.7] ) (30). There were no statistically significant differences between treatment groups at baseline in plasma selenium concentration (P ϭ 0.83) or in other participant characteristics, including lipid concentrations ( Table 1) . After 6 months of supplementation, plasma selenium had increased statistically significantly in the treatment groups but was unchanged in the placebo group ( Table 2 ). In addition, the 3 selenium groups had statistically significantly different lipid concentrations than those in the placebo group for all lipid variables ( Table 2) .
Selenium supplementation of 100 and 200 mcg per day for 6 months decreased total and non-HDL cholesterol levels. There was no statistically significant effect of the 300-mcg daily dose on total or non-HDL cholesterol levels, but this dose statistically significantly increased HDL cholesterol levels. The total-HDL cholesterol ratio was statistically significantly reduced after treatment with the 200-and 300-mcg daily selenium doses. Exclusion of the 22 participants who received lipid-lowering medication did not materially alter the results. In subgroup analyses, there were no statistically significant differences across study centers (Appendix Table, available at www.annals.org) or by
Original Research
Effect of Selenium Supplementation on Plasma Lipids sex, category of body mass index, baseline plasma selenium concentration, or baseline lipid concentrations (data not shown).
Association of Plasma Selenium Concentration With Lipid Levels
In cross-sectional analyses at baseline, increasing plasma selenium was associated with increasing total and HDL cholesterol levels and with decreasing total-HDL cholesterol ratio ( Table 3 and Appendix Figure 1 , available at www.annals.org). In longitudinal analyses, increasing plasma selenium concentrations from baseline to 6 months were associated with decreasing total cholesterol levels, non-HDL cholesterol levels, and the ratio of total-HDL cholesterol and with increasing HDL cholesterol levels ( Table 4 and Appendix Figure 2 , available at www.annals .org).
Adverse Events
No serious adverse events occurred. Twelve adverse events were reported, which were principally stomach or abdominal discomfort. These were equally associated with selenium or placebo and were not dependent on dose (data not shown).
DISCUSSION
Contrary to our original hypothesis, selenium supplementation of 100 and 200 mcg per day statistically significantly decreased total and non-HDL cholesterol concentrations. Supplementation of 300 mcg per day had a smaller and nonstatistically significant effect on total and non-HDL cholesterol levels, but it was the only dose that statistically significantly increased HDL cholesterol levels. The total-HDL cholesterol ratio decreased progressively Original Research Effect of Selenium Supplementation on Plasma Lipids with increasing selenium dose. Two previous trials of the effect of selenium supplementation on plasma lipids in 27 participants (25) and 40 participants (26) did not show any effects, although 1 trial reported a statistically significant decrease in the total-HDL cholesterol ratio after excluding 1 participant with a total cholesterol level less than 3.5 mmol/L (Ͻ135.1 mg/dL) (25).
The effect of selenium on lipid levels has also been extensively studied in experimental animal models in which selenium supplementation decreased plasma total and low-density lipoprotein cholesterol levels and increased HDL cholesterol levels, whereas selenium deficiency had the opposite effect (31-34). However, the relevance of such studies to humans is questionable.
Although we do not know the mechanisms underlying the effects of selenium on plasma lipids, several pathways involving selenium or selenoproteins are known to interact with both lipids and lipoproteins. Selenium is incorporated into selenoproteins as selenocysteine (Sec), which is dependent on its specific transfer RNA, designated as tRNA [ 
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Effect of Selenium Supplementation on Plasma Lipids www.annals.orgvolved in cholesterol biosynthesis, and decreased the expression of those involved in cholesterol metabolism and transport (35). Rescuing the mice with mutant Trsp transgenes that restored or partially restored several selenoprotein messenger RNAs and returned the levels of apolipoprotein E and cholesterol to those in normal mice suggests that 1 or more of these selenoproteins can decrease apolipoprotein E and plasma cholesterol concentrations (35). Furthermore, selenoprotein and cholesterol synthesis are connected through the common mevalonate pathway of isoprenoid biosynthesis (36). The rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase, is inhibited by statins resulting in a decrease in plasma cholesterol levels. Of interest, patients with dyslipidemia who received treatment with statins had lower plasma selenium concentrations than patients who did not receive treatment (37). Finally, selenium supplementation increases the production of 15-deoxy-⌬-12, 14-prostaglandin J2 (7, 38, 39), a known peroxisome proliferator-activated receptor-␥ ligand. Activation of peroxisome proliferator-activated receptor-␥ can reduce the concentration of sterol regulatory element-binding protein-2, resulting in a reduction of cholesterol synthesis (40). Our cross-sectional analysis of baseline data is consistent with findings from most observational studies that showed associations between high selenium status and elevated concentrations of total and HDL cholesterol (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , although the association with HDL cholesterol was particularly strong in our study. The results from our randomized, controlled trial, however, indicate that selenium supplementation may be more likely to reduce total cholesterol levels and increase HDL cholesterol levels. As a consequence, it now seems more likely that 1 or more unmeasured factors may increase both plasma selenium and total and non-HDL cholesterol levels, thus explaining the consistent cross-sectional associations. The implications of these findings for cardiovascular prevention are unclear. Randomized trials of seleniumcontaining supplements have not demonstrated a protective effect on cardiovascular disease or mortality end points (10 -13) . A meta-analysis of 14 cohort studies found a modest inverse association between biomarkers of selenium status, such as blood or toenail selenium concentrations, and the risk for coronary heart disease (10). However, no associations were seen between toenail selenium concentration and measures of subclinical atherosclerosis-that is, carotid intima-media thickness and coronary artery calcium score-in a study of 3112 young U.S. adults (41).
We think that the association of selenium status with cardiovascular outcomes will probably be influenced by the Original Research Effect of Selenium Supplementation on Plasma Lipids level of selenium status of the population studied. For instance, the absence of an effect of selenium supplementation on cardiovascular end points reported in 2 studies (11, 13) that used data from the NPC (Nutritional Prevention of Cancer) trial (mean plasma selenium concentration, 114 mcg/L) and SELECT (Selenium and Vitamin E Cancer Prevention Trial) (mean serum selenium concentration, 136 mcg/L) were in samples in which most selenoproteins, including glutathione peroxidase, would already have been optimized at baseline (42). Hence, if the potential beneficial effect of selenium on plasma lipids is dependent on increasing selenoprotein concentrations, no effect of supplementation would have been seen. By contrast, the risk for a cardiovascular event in patients with suspected coronary artery disease and considerably lower selenium status (mean plasma selenium, 74 mcg/L) followed for a median period of 4.7 years was shown to be inversely related to baseline intracellular glutathione peroxidase activity, illustrating a potentially beneficial effect of selenoprotein activity on cardiovascular risk (6) . Observational findings from the NHANES III (Third National Health and Nutrition Examination Survey) also support the idea that baseline selenium status may influence the apparent effect of supplementation insofar as they showed that above a certain plasma selenium concentration (at which we may assume that relevant selenoproteins have been optimized), there was no further advantage of higher selenium status in reducing cardiovascular mortality (43). This study has several limitations. We have shown an effect only on plasma lipids and not on cardiovascular disease risk, with lipid concentrations being, at best, only a surrogate measure of risk. Blood samples were collected in the nonfasting state, so total and HDL cholesterol concentration are likely to be accurate (44), but we could not measure plasma triglyceride levels, an additional coronary heart disease risk factor. Follow-up was only for 6 months, and we do not know whether the effect of selenium supplementation would differ over a longer period. Finally, with our sample size, we did not have sufficient power to evaluate subgroup effects reliably. In view of the relatively low baseline selenium status of the population, the limited duration of the intervention (6 months) and the limited age range of the group (60 to 74 years), further clinical trials are needed to corroborate our findings. HDL ϭ high-density lipoprotein. * To convert cholesterol values to mg/dL, divide by 0.02586. Results are from linear mixed models with random between-participant variations in both baseline lipid levels and lipid changes over time and adjusted for baseline selenium concentration (continuous), age (continuous), sex, study center (Bungay, Guisborough, Bromsgrove, or Linthorpe), smoking status (never, former, or current), body mass index (continuous), and use of lipid-lowering medications (Appendix, available at www.annals.org). † Overall P value comparing the 3 highest quartiles of selenium change with the lowest quartile.
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Our study was done in a sample in which few participants had maximized selenoprotein activities or concentrations. This would not have been the case in the United States, where mean serum selenium concentration, recently measured as 136.7 mcg/L (SD, 18.9) (45), is sufficient to optimize selenoprotein status in all but a few participants. In view of the potential public health implications of hyperlipidemia and the widespread use of seleniumcontaining supplements, our results are reassuring. However, the full range of cardiometabolic effects of selenium and its potential role in cardiovascular disease risk need to be further explored in larger randomized trials in populations that span the worldwide range of selenium intake.
In summary, selenium supplementation seemed to have modestly beneficial effects on plasma lipid levels in this sample of relatively low selenium status. Although the findings were statistically significant, their clinical significance is less clear. In that context, the findings perhaps more importantly suggest absence of harm of selenium supplementation in this set of metabolic measures (in which past evidence has suggested possible adverse effects) and should not be used to justify the use of selenium supplementation as additional or alternative therapy for dyslipidemia, particularly in persons with higher selenium status, given the limitations of the trial and the potential additional risk in other metabolic dimensions (46). 
Effect of Selenium Supplementation on Plasma Lipids mentation on plasma lipid levels within each center were imprecise but consistent with the overall results (Appendix Table) .
Cross-sectional and Longitudinal Associations Between Plasma Selenium and Lipid Concentrations
To assess the cross-sectional association of baseline selenium and lipid levels, as well as the longitudinal association between changes in plasma selenium and lipid levels over time, we developed additional linear mixed models for longitudinal data by using a 2-level hierarchical approach. The first-level model, which describes changes in within-participant plasma lipid levels Y ti from baseline t ϭ 0 to 6 months t ϭ 1, was identical to that of the intention-to-treat analysis:
At the second level, the individual baseline lipid levels ␣ 0i were allowed to vary as a linear function of the individual baseline selenium levels x 0i and other participant's characteristics measured at baseline z 0i , including age (continuous), sex, study center (Bungay, Guisborough, Bromsgrove, or Linthorpe), smoking status (never, former, or current), body mass index (continuous), and use of lipid-lowering medications. The individual changes in lipid levels from baseline to 6 months ␣ 1i were linearly related to the individual changes in selenium levels over time x 1i Ϫ x 0i . Thus, the second-level model was
in which the between-participant errors b 0i and b 1i were assumed to be independent and normally distributed with mean 0 and respective variances 0 2 and 1 2 . Combining the 2 nested models and noting that (x 1i Ϫ x 0i )t ϭ x ti Ϫ x 0i , we obtained the linear mixed model
In model (A2), the first line on the right-hand side represented the cross-sectional association of selenium levels and other covariates with plasma lipids at baseline. The fixed effect ␤ 00 represented the mean baseline lipid level at 0 values of selenium and other baseline covariates; the fixed effect ␤ 01 represented the covariate-adjusted mean change in baseline lipid levels per unit increase in baseline selenium levels; the fixed effects ␤ 02 represented the adjusted coefficients associated with the other baseline covariates; and the random effect b 0i represented the unexplained between-participant variation in baseline lipid levels. The mean changes in baseline levels of total cholesterol, HDL cholesterol, non-HDL cholesterol, and total-HDL cholesterol ratio per 50-ng/g (approximately the 10th to the 90th percentile) increase in baseline selenium levels estimated from model (A2) are shown in Table 3 . To assess nonlinear relationships, we modified the baseline portion of this mixed model to estimate the mean differences in baseline lipid levels for the 3 highest quartiles of baseline selenium levels compared with the lowest quartile ( Table 3) , as well as the mean baseline lipid changes on the basis of restricted quadratic splines (49) for baseline selenium levels with knots at the 5th, 50th, and 95th percentiles (61.0, 87.8, and 119.0 ng/g, respectively) (Appendix Figure 1) . In sensitivity analyses, we did standard multivariable linear regressions of plasma lipid concentrations on selenium levels by using only cross-sectional data from the baseline visit, with similar results (data not shown).
The second line of the linear mixed model (A2) represented the longitudinal association of changes in within-participant selenium levels with changes in within-participant plasma lipid levels adjusted for baseline covariates (50) . The fixed effect ␤ 10 represented the mean change in lipid levels from baseline to 6 months when selenium remained unchanged; the fixed effect ␤ 11 represented the covariate-adjusted rate of change in lipid levels over time per unit change in selenium levels; and the random effect b 1i represented the unexplained between-participant variation in lipid changes over time. The mean changes in levels of total cholesterol, HDL cholesterol, non-HDL cholesterol, and total-HDL cholesterol ratio over time for each 50-ng/g increase in within-participant selenium levels (approximately the mean increase after 6 months of selenium supplementation, 100 mcg/d) and for each quartile of change in selenium levels are shown in Table 4 . To allow for nonlinear longitudinal effects, we replaced the linear term x ti Ϫ x 0i in model (A2) with a restricted quadratic spline function (49) for within-participant selenium changes with knots at the 5th, 50th, and 95th percentiles (Ϫ8.0, 74.0, and 173.9 ng/g, respectively). The resulting smooth longitudinal trend is shown in Appendix Figure 2 . In sensitivity analyses, standard multivariable linear regression models relating changes in plasma lipid concentrations over time to changes in selenium levels yielded similar results (data not shown). Curves represent mean baseline lipid concentrations (solid line) and their 95% CIs (dashed line) based on restricted quadratic splines for baseline selenium concentrations, with knots at the 5th, 50th, and 95th percentiles (61.0, 87.8, and 119.0 ng/g, respectively). Results were obtained from linear mixed models with random between-participant variations in baseline lipid levels and adjusted for age, sex, center, smoking status, body mass index, and use of lipid-lowering medications (Appendix). To convert cholesterol values to mg/dL, divide by 0.02586. Scatterplots represent adjusted baseline concentrations of selenium and lipids. HDL ϭ high-density lipoprotein.
